GUD — Knight Therapeutics Income Statement
0.000.00%
Last trade - 00:00- CA$586.75m
- CA$473.08m
- CA$371.30m
- 96
- 42
- 70
- 80
Annual income statement for Knight Therapeutics, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 200 | 243 | 294 | 328 | 371 |
| Cost of Revenue | |||||
| Gross Profit | 81.7 | 115 | 138 | 153 | 174 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 232 | 256 | 332 | 328 | 364 |
| Operating Profit | -32.1 | -12.4 | -38.8 | 0.413 | 7.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 32.1 | 6.69 | -44 | -22 | 2.05 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 31.8 | 15.7 | -29.9 | -16.8 | 4.33 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 42.1 | 15.7 | -29.9 | -16.8 | 4.33 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 42.1 | 15.7 | -29.9 | -16.8 | 4.33 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.403 | 0.135 | -0.135 | -0.121 | 0.044 |